Cobra To Bio-Manufacture for Debiopharm

Cobra Biomanufacturing has entered into an agreement with Debiopharm S.A., a Swiss drug development company, for the manufacture of the biopharmaceutical protein huTNF-Alpha Kinoid. The agreement includes process development and supply of material for clinical trials. The new agreement replaces a prior manufacturing deal with Neovacs SA that has licensed the program to Debiopharm. David Thatcher, chief executive officer of Cobra, said, “We are pleased to continue with the process development aspect of the TNF-Alpha Kinoid project while forging a new relationship with Debiopharm. This agreement recognizes Cobra’s previous success in this project and our expertise in producing therapeutic protein vaccines.”